CD8A and neoplasm: Transfer of CD8αβ in combination with intermediate affinity tumor reactive αβTCR has been reported to support tumor control in vitro and in vivo (49, 50), and for high affinity αβTCR with artificial signaling domains adding CD8α alone has been shown to reprogram CD4+ T cells (36).